Natural GLP-1 produced by your body has a half-life of about 1 to 2 minutes
[2] Since then, several other GLP-1 agonists have been developed and approved for clinical use, including liraglutide (Victoza), dulaglutide (Trulicity), semaglutide (Ozempic and Wegovy), and Tirzepatide (Mounjaro and Zepbound)
i am happy with the quality so far
Several candidates are advancing through clinical development, including orforglipron, currently in Phase III trials for obesity and type 2 diabetes
Its triple-receptor action may provide more comprehensive effects than single-target medications
We know GLP-1s are mostly used for weight loss, but how do the drugs (like Ozempic, Wegovy, Mounjaro) interact with the endocrine system beyond appetite and metabolism